TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

Rhea-AI Summary

TransMedics Group, Inc. (NASDAQ: TMDX) will announce its fourth quarter and full year 2022 financial results on February 22, 2023, after market close. A conference call will follow at 4:30 p.m. ET. Investors can access the call by dialing (866) 807-9684 domestically or (412) 317-5415 internationally. TransMedics specializes in portable extracorporeal warm perfusion and organ assessment technology, aimed at improving organ transplantation outcomes for patients suffering from end-stage heart, lung, and liver diseases.

Positive

• Focus on enhancing organ viability and transplantation outcomes.
• Scheduled release of Q4 and full year 2022 financial results indicates transparency.

Negative

• None.

ANDOVER, Mass., Feb. 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2022 after market close on Wednesday, February 22, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. 

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023-301740471.html

SOURCE TransMedics Group, Inc.

FAQ

When will TransMedics report its financial results?

TransMedics will report its financial results for Q4 and full year 2022 on February 22, 2023.

What time is the TransMedics conference call?

The conference call will begin at 4:30 p.m. ET on February 22, 2023.

How can I participate in the TransMedics conference call?

Investors can join the call by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers.

What is the main focus of TransMedics?

TransMedics focuses on portable extracorporeal warm perfusion and assessment technologies to improve organ transplantation.